Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
AbstractClinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treating RA patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of RA patients treated with biological response modifiers, which contains all of the demographic and clinical parameters, as well as the therapeutic data, usually needed to follow RA patients...
- Abstract views: 1656
- PDF: 821
Copyright (c) 1970 P. Sarzi- Puttini, M. Antivalle, A. Marchesoni, E.G. Favalli, R. Gorla, M. Filippini, R. Caporali, F. Bobbio-Pallavicini, C. Montecucco, F. Atzeni
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.